A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether there is an optimal antithrombotic management for patients supported with axial-flow left ventricular assist devices (LVADs). Altogether, more than 758 papers were found using the reported search, of which 17 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. These included seven prospective and three retrospective cohort studies with a total of 538 patients with axial-flow left ventricular assist device (LVAD) (HeartMate II, Jarvik 2000, INCOR, Thoratec assist device) implanted across the world as destination therapy or bridge to transplantation. We conclude that there is a substantial alteration of the prothrombotic profile in patients with axial-flow LVADs. These abnormalities appeared to be reversible with the removal of the device and are likely to be responsible for the high incidence of non-surgical bleeding episodes reported. Warfarin seems to offer a lower thromboembolic risk compared with unfractioned heparin or low molecular weight heparin. There are reports that suggest that managing axial-flow LVAD without anticoagulation, after major bleeding complications, is possible but in all probability, these papers are subject to publication bias as poor outcomes are unlikely to have been reported. All patients with axial-flow LVAD, showed severely impaired platelet function at point of care tests. The use of warfarin (INR target 2.5), in association with aspirin at 100 mg/day, or with point-of-care tests titrated antiplatelet therapy to inhibit 70%, seems to have the best bleeding-thrombosis, and in many cases a very small dose of aspirin of 25 mg twice a day and a dose of clopidogrel of 35 mg/day, were sufficient to achieve a reduction of the maximum aggregation to less than 30%. Finally, we would like to emphasize that such recommendations are addressed only to patients with axial-flow LVAD.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] THREE-PART QUESTION 
CLINICAL SCENARIO
You are at a ventricular assist device (VAD) conference and the speaker is talking about the problems that they have been having with non-surgical bleeding at their institution. You are surprised as in your institution you have not had many bleeding complications, but have had a few serious ventricular assist device (VAD) thromboses, which all required thrombolysis to resolve. You wonder what the current anticoagulation strategies are around the world and resolve to check the literature.
SEARCH STRATEGY
Medline 1950 to March 2012 using OVID interface (left ventricular assist device/or LVAD.mp.) and (antithrombotic therapy/or anticoagulation.mp.) SEARCH OUTCOME 758 papers were found using the reported search. From these, 17 papers were identified. That provided the best evidence to answer the question. They are presented in Table 1 . Anticoagulation protocol Heparin IV was started once chest tube drainage was <0.5 ml/kg/h . Dipyridamole was started immediately postoperatively IV at 0.1 mg/kg/h in children <6 years old, 50 mg (age 6-10 years) or 100 mg (>10 years) every 6 h. Aspirin was started at 2-10 mg/kg/min after plt > 150 000 mm 3 . Dosage was increased in larger children by 162-325 mg for each 100 000 plt above 150 000. Pentoxifylline 400 mg × 3/daily was used in >6-years old VAD anticoagulation is more difficult in children. 20/28 (71%) were discharged from the hospital. Antiplatelet effect assessed with thromboelastography (TEG), platelet aggregation studies Continued aspirin and dipyridamole, reported an incidence of gastrointestinal (GI) bleeding events of 44.3%. Anticoagulant use was not statistically different between bleeders and non-bleeders, with an average INR at time of bleeding of 1.67 ± 0.53. Stern et al. [3] similarly reported an incidence of GI bleeding of 40% in the HeartMate II (HM II) axial-flow LVAD, group versus 0% in the pulsatile one. The anticoagulation protocol consisted of a low-dose of aspirin and dipyridamole and warfarin (INR of 2.0-3.0). Interestingly, 3 bleeding patients uneventfully withheld warfarin for about four months.
Demirozu et al. [4] , in a large series of 172 patients, supported with HM II and anticoagulated with warfarin aspirin and dipyridamole, reported a GI bleeding rate of 32%. They demonstrated the presence of an arteriovenous malformation in 31% of the bleeding patients.
Geisen et al. [5] demonstrated that their axial-flow LVAD patients developed impaired coagulation secondary to acquired von Willebrand syndrome (AvWS).
Crow et al. [6] , in a multicenter prospective study, investigated the impact of continuous flow LVAD support on the haemostatic profile in 37 patients. All LVAD recipients developed AvWS after the device implantation, but only 10 had bleeding complications. The anticoagulation protocol consisted of warfarin (INR target 1.5-2.0) and aspirin. INR levels between bleeders and non-bleeders were similar. Point of care test for the evaluation of platelet function was not used. They conclude that the loss of high-molecular-weight von Willebrand factor multimers alone cannot predict bleeding risk.
Meyer et al. [7] showed the reversibility of AvWS in 26 patients supported with axial-flow LVAD implanted as bridge to transplantation after the removal of the device. During LVAD support they reported an incidence of bleeding of 0.17 per patient-year using warfarin (INR target 2.5 ± 0.5) and Aspirin 100 mg/day. If a patient was diagnosed with AvWS, aspirin was stopped. One patient had fatal mesenteric ischaemia. Platelet function analyser showed severe impairment in all patients on LVAD support.
Jennings et al. [8] reported that their outpatient HM II cohort (16 patients) spent 32% of the average time below the therapeutic INR range (2.0-3.0) with only one incidence of TIA and no incidence of GI bleeding episodes. The authors did not comment about antiplatelet therapy.
Slaughter et al. [9] , showed that, despite high shear stresses associated with a high-speed axial flow pump, there was no effect on platelet activation, independently of length of support, antiplatelet and anticoagulation regimens used.
John et al. [10] , in their series of 45 patients supported with HM II, successfully reduced the intensity of anticoagulation (avoiding postoperative heparin infusion, decreasing the therapeutic INR to 1.5-2.0 and introducing aspirin at 81 mg/day from post op day 2-3), without any increase in thromboembolic events.
Attisani et al. [11] successfully used a platelet aggregation test (PAT) to reduce the dose of antiplatelet in 14 patients supported with the INCOR LVAD and anticoagulated with warfarin (INR target 2.8-3.2). They showed that 82% required a dose of aspirin of 25 mg twice a day and 90% a dose of clopidogrel of 35 mg/ day, to reduce the maximum aggregation <30%. They reported no GI bleeding episodes and a rate of major and minor thromboembolic events of 0.09 and 0.2 per patient-year, respectively.
Meuris et al. [12] , in 10 patients supported with the INCOR LVAD implanted as bridge-to-transplantation, suggested the use of the low molecular weight heparin (LMWH) (1 mg/Kg twice daily) and triple antiplatelet therapy (aspirin at 80 mg two times daily; clopidogrel at 75 mg daily; and dipyridamole 75 mg three times daily) as an alternative to oral anticoagulants. PAT was used to reduce platelet aggregation levels to at least 30%. They reported 1 severe stroke with concomitant fatal intracranial bleeding and 4 Thrombus-related pump dysfunction.
Copeland et al. [13] , similarly in children with LVAD used IV heparin associated with point-of-care titrate antiplatelet therapy consisting of: Aspirin 2-10 mg/kg/min increased in larger children by 162-325 mg for each 100 000 platelets above 150 000; dipyridamole, IV at 0.1 mg/kg/h in children <6 years old, 50 mg (age 6-10 years) or 100 mg (>10 years) by mouth every 6 h; pentoxifylline 400 mg per os three times daily(age > 6). This experience was worrisome, with 20% incidence of reoperation for bleeding and 25% of stroke (2 fatal).
Saito et al. [14] , in an animal model, successfully supported the systemic circulation with continuos flow LVAD without any anticoagulation up to 210 days.
Pereira et al. [15] reported 2 axial-flow LVAD patients who stopped anti-thrombotic therapy for more than a year because of recurrent GI bleeding episodes, without any thrombotic complications.
Steinlechner et al. [16] , simultaneously used thrombelastography (TEG), rotation thromboelastometry (ROTEM), platelet function analyser (PFA-100) and multiplate, on 12 patients supported with continuous flow LVAD. They showed markedly impaired platelet function independently from the effect of the anticoagulation therapy with warfarin (INR target 2.5-3.5) and aspirin 100 mg/day. Tsukui et al. [17] , in a retrospective analysis of 124 patients with axial-flow LVAD and biventricular assist device (BIVAD) anticoagulated with warfarin (INR 2.5-3.5) and aspirin (81-325 mg/day) e/o clopidogrel 75 mg/day to maintain the maximum amplitude (MA) on the TEG between 60-70 mm, reported 25% of cerebrovascular accidents (CVAs), 42% happening in patients with infections. The mean MA in the presence of infection (63.6 mm) was higher than that in the absence of infection (60.7 mm) (P = 0.0309).
CLINICAL BOTTOM LINE
There is a substantial alteration of the prothrombotic profile in patients with axial-flow LVADs. These abnormalities appeared to be reversible with the removal of the device and are likely to be responsible for the high incidence of non-surgical bleeding episodes reported. Warfarin seems to offer a lower thromboembolic risk compared with unfractioned heparin or LMWH. There are reports that suggest that managing axial-flow LVAD without anticoagulation, after major bleeding complications, is possible, but in all probability these papers are subject to publication bias as poor out-comes are unlikely to have been reported. All patients with axial-flow LVAD showed severely impaired platelet function at point of care tests. The use of warfarin (INR target 2.5), in association with aspirin at 100 mg/day, or with point-of-care tests titrated antiplatelet therapy to inhibit 70%, seems to have the best bleedingthrombosis, and in many cases a very small dose of aspirin of 25 mg twice a day and a dose of clopidogrel of 35 mg/day, were sufficient to achieve a reduction of the maximum aggregation to less than 30%. Finally, we would like to emphasize that such recommendations are addressed only to patients with axial-flow LVAD.
